linjc16/ctgov huggingface dataset:
Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail

Study Overview
=================
Brief Summary
-----------------
To compare the renal protective properties of two currently used anaesthetic techniques - a sevoflurane-remifentanil/sufentanil combination with a propofol-remifentanil/sufentanil combination for anaesthesia in patients undergoing living donor kidney donation/transplantation.

Official Title
-----------------
Volatile Anesthetic Protection Of Renal Transplants: VAPOR-1-trail

Conditions
-----------------
Kidney Donation/Transplantation

Intervention / Treatment
-----------------
* Drug: procedure:sevoflurane-remifentanil/sufentanil
* Drug: volatile agent only during reperfusion
* Drug: propofol-remifentanil/sufentanil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients: Age > 18 years Exclusion Criteria: patient refusal BMI< 17, >35 neurological disorder recent use of psycho-active medication, including alcohol. Donor-recipient couples from the ABO-incompatible program Altruistic donor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: SEVO<br>sevoflurane-remifentanil/sufentanil combination | Drug: procedure:sevoflurane-remifentanil/sufentanil<br>* Active Comparator<br>|
| Active Comparator: SERE<br>volatile agent only during reperfusion | Drug: volatile agent only during reperfusion<br>* Active Comparator<br>|
| Active Comparator: propofol<br>propofol-remifentanil/sufentanil | Drug: propofol-remifentanil/sufentanil<br>* Active Comparator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the renal protective properties of two currently used anaesthetic techniques |  | participants will be followed for the duration of hospital stay | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
renal, transplantation, Volatile, anesthetic
The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effectiveness of intravitreal autologous platelet concentrate (APC) injection during the surgery for refractory macular holes.

Conditions
-----------------
Macular Hole With High Myopia (Spherical Equivalent ≤ -6.0 Diopters) or,, Large Size Macular Hole (Diameter > 600 Microns) or, Recurred or Failed Macular Hole From Previous Surgery, or Chronic Macular Hole (Symptom Duration > 6 Months)

Intervention / Treatment
-----------------
* Procedure: Autologous platelet concentrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Macular hole with any of following condition High myopia (spherical equivalent ≤ -6.0 Diopters) Large size macular hole (Diameter > 600 microns) Recurred or failed macular hole from previous surgery Chronic macular hole (symptom duration > 6 months) Exclusion Criteria: Systemic infection Hematologic disease Severe maculopathy including severe diabetic retinopathy, advanced age-related macular degeneration

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: autologous platelet concentrate<br> | Procedure: Autologous platelet concentrate<br>* pars plana vitrectomy internal limiting membrane removal Fluid-air exchange Intravitreal autologous platelet concentrate injection Intravitreal gas (14% C3F8) injection Keep prone position for 7-14 days after surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| macular hole closure |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| best-corrected visual acuity |  | 6 months | 
| metamorphopsia score |  | 6 months | 
| safety outcome | frequency and severity of ocular adverse event | 6 months |
Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis

Study Overview
=================
Brief Summary
-----------------
Ocular toxoplasmosis is the most common cause of infectious uveitis worldwide. The diagnosis of ocular toxoplasmosis is primarily clinical when it is a typical presentation .With an atypical presentation in the fundus, parasitological diagnosis is a decisive contribution, as well as multimodal imaging. We investigate on vitreal, retinal, and choroidal morphologic changes in active and scarred toxoplasmosis lesions using swept source optical coherence tomography.

Detailed Description
-----------------
A retrospective analysis of patients diagnosed with ocular toxoplasmosis was conducted. The patients were examined at ophthalmology service of Farhat Hached Hospital in Sousse Tunisia between January 2002 and December 2017. Complete ophthalmologic examination and OCT were done at the initial visit and during follow-up.

Official Title
-----------------
Spectral Optical Coherence Tomography Findings in Patients With Ocular Toxoplasmosis : a Retrospective Study

Conditions
-----------------
Ocular Toxoplasmosis

Intervention / Treatment
-----------------
* Diagnostic Test: Spectral optical coherence tomography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients hospitalized for ocular toxoplasmosis. Exclusion Criteria: patients with non active ocular toxoplasmosis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Spectral optical coherence tomography|Swept-source optical coherence tomography (SS-OCT) is the latest milestone in retinal and choroidal imaging. Because its wavelength of 1050 nm, which is superior to the 840 nm of spectral domain optical coherence tomography (SD-OCT), it is able to overcome ocular opacities such as cataracts and vitritis, wich allows retinal and choroidal visualization of eyes whose fundus is not clearly visible. Consequently , SS-OCT allows visualization of the retinal and choroidal vascular networks, even in eyes with medium opacity|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of prticipant affected with ocular toxoplasmosis | patient diagnosed having ocular toxoplasmosis | up to one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Spectral optical coherence tomography, Ocular toxoplasmosis, Uveitis
Transtheoretical Model of Behavior Change and Anxiety

Study Overview
=================
Brief Summary
-----------------
Examine the utility of the Transtheoretical Model in influencing anxiety among college students. Employ a randomized controlled intervention including a static and dynamic Facebook intervention. The static group accessed a Facebook page featuring 96 statuses. Statuses were intended to engage cognitive processes, followed by behavioral processes of change per the Transtheoretical Model of behavior change. Content posted on the static Facebook page was identical to the dynamic page. However, the static group viewed all 96 statuses on the first day of the study, while the dynamic group received only 1-2 of these status updates per day throughout the intervention. Anxiety was measured using the Overall Anxiety Severity and Impairment Scale (OASIS). Time spent engaging in physical activity was assessed using the International Physical Activity Questionnaire (IPAQ).

Official Title
-----------------
Can Facebook Reduce Perceived Anxiety Among College Students? A Randomized Controlled Exercise Trial Using the Transtheoretical Model of Behavior Change

Conditions
-----------------
Psychological, Physical Activity

Intervention / Treatment
-----------------
* Behavioral: Transtheoretical Model


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Having an active Facebook account Daily access to a Smart Phone Current University of Mississippi email account Exclusion Criteria: Outside the age range of 18-35

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Static<br> | Behavioral: Transtheoretical Model<br>* Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).<br>|
| Experimental: Dynamic<br> | Behavioral: Transtheoretical Model<br>* Exposure to content on Facebook, either daily (dynamic) or just at one time period (static).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in Anxiety | OASIS, Overall Anxiety Severity and Impairment Scale. There are 5 questions in this scale, with each question including 5 response options (ranging from 0-4). The total score is reported, which ranges from 0-20 (higher score indicates greater anxiety). | At baseline and at the end of the 8-week intervention |
Virtual Anatomical Reconstruction of Mandibular Bone Defects Using a Statistical Shape Model

Study Overview
=================
Brief Summary
-----------------
Hundred already taken CT-scans (50 male and 50 female) will be anonymized. These scans will be segmented and implemented into a statistical shape model that will be used to predict missing hard tissue of a mandible based on the remaining bone.

Detailed Description
-----------------
Together with the radiology and Craniomaxillofacial (CMF) department, 100 scans will be selected from the database (50 males and 50 females, between 20 and 60 years old). First, they will be anonymized (except the sex and age/date of birth). Afterwards, they will be segmented using Materialise Mimics software. The segmented mandibles will then be used to create a statistical shape model (SSM) using principal component analysis. This model will afterwards be used to predict the mandibular shapes.

Official Title
-----------------
Virtual Anatomical Reconstruction of Mandibular Bone Defects Using a Statistical Shape Model

Conditions
-----------------
SSM, Mandibular Diseases

Intervention / Treatment
-----------------
* Other: CT-scan evaluation and segmentation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy mandibles Exclusion Criteria: Mandibles with major deformities Mandibles with obvious problems Mandibles that already underwent surgery

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy mandibles<br>Belgian adults (between 20 and 60 years old), 50/50 male/female, with no major mandibular problems/deformities | Other: CT-scan evaluation and segmentation<br>* CT-scans will be evaluated (to see if they are included in the research group) and segmented if they are accepted.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A statistical shape model of a mandible | A statistical shape model of a mandible | 2 months |
Estimated Blood Loss: Novel Model for Estimating Surgical Blood Loss.

Study Overview
=================
Brief Summary
-----------------
Estimated blood loss is an important parameter recognized as a standard practice in anesthesiology and others medical specialties, with relevant clinical and research applications. Currently is no model capable of accurately estimate blood loss. The purpose of this study is to evaluate the accuracy of a novel model.

Official Title
-----------------
Estimated Blood Loss: Novel Model for Estimating Surgical Blood Loss.

Conditions
-----------------
Blood Loss, Surgical, Blood Loss, Blood Loss, Postoperative

Intervention / Treatment
-----------------
* Other: Measurement of external blood loss
* Diagnostic Test: Serum Hemoglobin concentration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for elective urologic laparoscopy surgery. Exclusion Criteria: Patient with suspected or confirmed heart failure, severe hypertension, hepatic cirrhosis, chronic kidney disease on dialysis, coagulopathy, as well as patient receiving diuretics, anticoagulant or antiplatelet agents. Cases in which surgical gauzes were used, including conversion to open surgical technique. - Patients who have received transfusions of RBCs during the perioperative period. Patients who have showed postoperative bleeding, defined by an amount greater than 50 ml in surgical drains, or any other type of blood loss.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Measurement of external blood loss|nan|
|Diagnostic Test: Serum Hemoglobin concentration|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hemoglobin mass lost |  | Intraoperative | 
| Postoperative serum hemoglobin concentration |  | 48 hours |
Borderline COVID-19 PCR Test Result

Study Overview
=================
Brief Summary
-----------------
Follow-up of patients with a borderline PCR result. Data of patients that were re-tested within 96 hours after receiving a borderline COVID-19 PCR result are reviewed. This is a retrospective study.

Official Title
-----------------
Follow-up of Patients With a Borderline COVID-19 PCR Test Result

Conditions
-----------------
Covid19, Virus

Intervention / Treatment
-----------------
* Diagnostic Test: SARS-CoV-2 PCR


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every individual that delivers a nasopharyngeal lysate for SARS-CoV-2 RNA determination by PCR. Exclusion Criteria: Patients without a previous borderline COVID-19 PCR result within 96 hours are excluded for the follow-up study.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| COVID-19 suspected by symptoms, after high-risk contact or after a borderline PCR result.<br> | Diagnostic Test: SARS-CoV-2 PCR<br>* SARS-CoV-2 PCR of nasopharyngeal lysate.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ratio of positivity conversion after receiving a COVID-19 borderline PCR result. |  | 3 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms predicting COVID-19 positivity conversion after receiving a borderline PCR result. |  | 1 day |
Study of Tolerance to Oral Peanut

Study Overview
=================
Brief Summary
-----------------
Open pilot study of peanut oral immunotherapy in 22 children with peanut allergy

Detailed Description
-----------------
Background Peanut allergy is severe and rarely resolves. Objective To test the efficacy and safety of a new oral immunotherapy protocol for peanut allergy. Method 22 peanut-allergic children will undergo oral challenge. Oral immunotherapy will be administered by gradual updosing with 2-weekly increments (8-38w) to 800mg protein (5 peanuts/day) followed by 30-weeks maintenance. Oral challenge will be repeated after 6 and 30 weeks maintenance.

Official Title
-----------------
Efficacy and Safety of High-dose Peanut Oral Immunotherapy With Factors Predicting Outcome

Conditions
-----------------
Peanut Allergy

Intervention / Treatment
-----------------
* Dietary Supplement: Peanut oral immunotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Peanut allergy defined by oral challenge Exclusion Criteria: Major immunodeficiency

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Peanut immunotherapy<br>Peanut flour | Dietary Supplement: Peanut oral immunotherapy<br>* Daily doses of peanut flour<br>* Other names: Daily doses peanut flour;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pass/fail peanut challenge |  | six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peanut, food allergy, anaphylaxis, immunotherapy
PANDA: PKU Amino Acid Evaluation

Study Overview
=================
Brief Summary
-----------------
Phenylketonuria (PKU) is a rare inherited metabolic disorder, where subjects are born with a genetic deficiency in the phenylalanine hydroxylase enzyme (PAH), which leaves them unable to convert Phenylalanine (Phe) into Tyrosine (Tyr). PKU patients have specific dietary needs and must follow a restrictive diet in the aim of preventing toxic levels of the amino acid phenylalanine (Phe) accumulation.

Detailed Description
-----------------
The exploratory study's main objective is to measure blood amino acid levels and to gain quantitative insights in children with PKU on a protein substitute with respect to evaluation of nutritional intake.

Official Title
-----------------
PANDA: A Cross-sectional Study to Measure Blood Amino Acid Levels in PKU Children on a Protein Substitute

Conditions
-----------------
Phenylketonuria (PKU)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both PKU and Non-PKU comparison subjects: Age ≥ 2 and ≤ 12 years Willing and able to provide informed consent by parents or legal representatives (and assent if required by local law/regulations) One subject per family PKU subjects specific inclusion criteria: PKU subjects identified by newborn screening and started low Phe diet before 1 month age Usage of at least two Phe-free protein substitutes on a daily basis for at least 26 consecutive weeks up to Visit 1 Average Phe-level ≤360 µmol/L based on at least two blood Phe values from the past 12 months up to Visit 1 Non-PKU comparison subjects specific inclusion criteria: Same age (±3 years) and sex as an included PKU subject Exclusion Criteria: Both PKU and Non-PKU comparison subjects: Current psychiatric disorders Severe hepatic, thyroid or renal dysfunction Acute illnesses like fever, flu, diarrhea, or vomiting (subjects should be symptom free for a week prior to V1) Serious conditions (e.g. cancer, hydrocephalus, fatal heart disease) Participation in any other clinical intervention studies involving test products concomitantly or within six weeks prior to entry into the study PKU specific exclusion criteria: Use of BH4, or drugs that may interfere with main outcomes Non-PKU comparison subjects specific exclusion criteria: PKU diagnosis or any other diagnosed disorder of amino or organic acid metabolism

Ages Eligible for Study
-----------------
Minimum Age: 2 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Children with PKU<br> | |
| Age- and sex-matched non-PKU comparison subjects<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amino acid levels in blood | Measuring amino acid levels in blood [μmol/L] | day 1 | 
| Nutrient Intake | Measured by three-day diet diary. Nutrients in [mg/day] | day 1 - day 3 |
Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute

Study Overview
=================
Brief Summary
-----------------
This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset® T).

Conditions
-----------------
Orthopedic Operations

Intervention / Treatment
-----------------
* Drug: tobramycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult (> or =18 years old) patients Treatment with Osteoset® T Exclusion Criteria: Intravenous tobramycin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| adult patients treated with Osteoset® T (tobramycin sulfate)<br>10 g or 20 g of Osteoset® T | Drug: tobramycin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measurement of systemic tobramycin concentration | Develop a population pharmacokinetic model for tobramycin in patients treated with an active calcium sulfate bone substitute and to predict tobramycin systemic exposure under various dose and renal function levels. | within 10 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tobramycin, bone graft substitute, pharmacokinetics, renal failure